Medivation Inc. (MDVN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Medivation ( MDVN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.2%. By the end of trading, Medivation rose $8.51 (11.2%) to $84.29 on heavy volume. Throughout the day, 6,337,464 shares of Medivation exchanged hands as compared to its average daily volume of 1,011,400 shares. The stock ranged in a price between $82.60-$87.46 after having opened the day at $86.00 as compared to the previous trading day's close of $75.78. Other companies within the Drugs industry that increased today were: Horizon Pharma ( HZNP), up 18.2%, Prothena Corporation ( PRTA), up 9.8%, Tianyin Pharmaceutical ( TPI), up 9.6% and Delcath Systems ( DCTH), up 7.6%.

Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Medivation has a market cap of $5.5 billion and is part of the health care sector. Shares are up 18.7% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Medivation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Medivation as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk.

On the negative front, Progenics Pharmaceuticals ( PGNX), down 27.4%, Idenix Pharmaceuticals ( IDIX), down 10.4%, Relypsa ( RLYP), down 8.7% and Hemispherx Biopharma ( HEB), down 7.8% , were all laggards within the drugs industry with Amgen ( AMGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors